Pharmaco-Pheno-Multiomic Integration Reveals Biomarker Profiles and Therapeutic Response Prediction Models in Leukemia and Ovarian Cancer

Author:

Silberberg Gilad,Walling Brandon,Wesa Amy,Audia Alessandra,Sloma Ido,Zeng Yi,Han Guanghui,Tang Jia,Pammer Paige,Bakayoko A’ishah,Ren Xuan,Ciznadija Daniel,Vishwakarma Bandana,Mosesson Yaron,Zipeto Marianna,Ritchie Michael

Abstract

AbstractDespite considerable progress made in improving therapeutic strategies, the overall survival for patients diagnosed with various cancer types remains low. Further, patients often cycle through multiple therapeutic options before finding an effective regimen for the specific malignancy being treated. A focus on building enhanced computational models, which prioritize therapeutic regimens based on a tumor’s complete molecular profile, will improve the patient experience and augment initial outcomes. In this study, we present an integrative analysis of multiple omic datasets coupled with phenotypic and therapeutic response profiles of Cytarabine from a cohort of primary AML tumors, and Olaparib from a cohort of Patient-Derived Xenograft (PDX) models of ovarian cancer. These analyses, termed Pharmaco-Pheno-Multiomic (PPMO) Integration, established novel complex biomarker profiles that were used to accurately predict prospective therapeutic response profiles in cohorts of newly profiled AML and ovarian tumors. Results from the computational analyses also provide new insights into disease etiology and the mechanisms of therapeutic resistance. Collectively, this study provides proof-of-concept in the use of PPMO to establish highly accurate predictive models of therapeutic response, and the power of leveraging this method to unveil cancer disease mechanisms.

Publisher

Cold Spring Harbor Laboratory

Reference46 articles.

1. Administration, F.a.D. List of cleared or approved companion diagnostic devices (In Vitro and Imaging Tools). 2022 3/17/2022; Available from: https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools.

2. NIH. Cancer Stat Facts: Leukemia-Acute Myeloid Leukemia (AML). Surveillance, Epidemiology, and End Results Program 2021; Available from: https://seer.cancer.gov/statfacts/html/amyl.html.

3. Acute Myeloid Leukemia

4. Institute, N.C. Surveillance, Epidemiology, and End Results. 2022; Available from: https://seer.cancer.gov/explorer/.

5. Ovarian cancer;Nat Rev Dis Primers,2016

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3